Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
N/A
A retrospective study of de-identified (to preserve patient privacy) patien...
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
PHASE3
A study to compare the safety and efficacy of an aromatase inhibitor in com...
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
PHASE2
This prospective, response-adapted phase II study evaluates the efficacy an...
Status
Recruiting
Location
The First Affiliated Hospital of Nanjing Medical University
Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer
N/A
RATIONALE: Studying samples of blood in the laboratory from patients with c...
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
PHASE3
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone th...